GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Inventories, Finished Goods

Regeneron Pharmaceuticals (FRA:RGO) Inventories, Finished Goods : €134 Mil (As of Dec. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Regeneron Pharmaceuticals Inventories, Finished Goods?

Regeneron Pharmaceuticals's quarterly finished goods increased from Jun. 2024 (€143 Mil) to Sep. 2024 (€148 Mil) but then declined from Sep. 2024 (€148 Mil) to Dec. 2024 (€134 Mil).

Regeneron Pharmaceuticals's annual finished goods increased from Dec. 2022 (€93 Mil) to Dec. 2023 (€135 Mil) but then declined from Dec. 2023 (€135 Mil) to Dec. 2024 (€134 Mil).

Regeneron Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Regeneron Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Inventories, Finished Goods Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.04 65.23 93.08 135.07 133.51

Regeneron Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.07 166.06 143.44 148.31 133.51

Regeneron Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Regeneron Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Inventories, Finished Goods
Comparable Companies
ALNY ONC BNTX SMMT INSM BMRN RPRX VRTX MRNA INCY ASX:CSL XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 HKSE:02269 XKRX:196170 OCSE:GMAB SHSE:603392 EXEL
Traded in Other Exchanges
REGN:USA REGN:Mexico 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines